A retrospective study to alter gut microbiome balance on pembrolizumab (PEM) efficacy in metastatic urothelial carcinoma (mUC) patients
Latest Information Update: 27 Oct 2021
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Bladder cancer; Carcinoma; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- 27 Oct 2021 New trial record
- 13 Sep 2021 Results presented at the 116th Annual Meeting of the American Urological Association.